TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

TELA Bio, Inc.NASDAQ: TELA

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity turns negative

Q2 FY2026 total equity was -$15.87M, compared with $9.18M a year earlier. Over 3 fiscal years it compounded at -23.9% a year.

Context

  • Total equity amounted to 26.6% of total assets at the end of Q2 FY2026, up 13.0 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -272.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$15.87M-205.1% QoQ
Last fiscal yearDec 2025
$6.31M-77.8% YoY
Year agoJun 2025
$9.18M-272.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-272.8%——
1 year-77.8%——
3-year CAGR-23.9%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
6.31M USD
Year-over-year change
-77.8%
4-year CAGR
-25.1%

Total Equity vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's Jun 2026 total equity of -$15.87M is the 8th highest of the 9 companies compared; the peer median is $19.59M.
  • Its year-over-year change of -272.8% is the 8th highest of 9, against a peer median of +85.6%.
  • Total equity amounts to 26.6% of total assets for TELA, versus a peer median of 88.6%.
TELA Competitors Peer median
Total Equity for TELA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EQEquillium, Inc.Mar 2026$59.49M +462.4%-3.6%94.3%
SRTSSensus Healthcare, Inc.Mar 2026$45.54M -14.1%+0.0%88.4%
SPRBSpruce Biosciences, Inc.Mar 2026$34.65M +126.1%-14.7%61.7%
CUECue Biopharma, Inc.Mar 2026$21.61M +228.4%-26.2%70.0%
COEPCoeptis Therapeutics, Inc.Mar 2026$17.58M +135.5%+58.6%88.8%
MDAISpectral AI, Inc.Mar 2026-$8.81M -441.8%—49.7%
NRXPNRx Pharmaceuticals, Inc.Mar 2026-$13.82M +45.1%—116.1%
TELATELA Bio, Inc.Jun 2026-$15.87M -272.8%-23.9%26.6%
OTLKOutlook Therapeutics, Inc.Mar 2026-$28.99M +10.7%—132.4%
Peer median (excluding TELA) $19.59M+85.6%-3.6%88.6%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents43.93M42.02M46.73M52.67M50.85M
Short-term Investments00000
Net Receivables4.23M6.62M9.74M10.1M10.35M
Inventory7.66M11.79M13.16M12.78M11.02M
Other Current Assets02.02M2.1M2.52M3.37M
Total Current Assets59.06M62.45M71.73M78.07M75.58M
Property, Plant & Equipment (Net)1.19M2.91M3.94M4.08M3.73M
Goodwill00000
Intangible Assets2.3M2.5M2.12M1.74M1.36M
Long-term Investments00265K2.54M250K
Tax Assets000896K0
Other Non-current Assets0000500K
Total Non-current Assets3.49M5.41M6.32M9.25M5.84M
Total Assets62.54M67.86M78.05M87.33M81.42M
Account Payables2.41M1.53M1.67M2.15M2.31M
Short-term Debt0340K565K545K0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.15M4.11M5.52M5.56M15.67M
Total Current Liabilities10.58M12.4M16.97M15.6M17.98M
Long-term Debt31.49M39.92M40.52M41.12M55.65M
Deferred Tax Liabilities000756K0
Deferred Revenue (Non-current)00000
Other Non-current Liabilities380K31K001.48M
Total Non-current Liabilities31.87M41.15M42.2M43.27M57.13M
Total Liabilities42.45M53.55M59.17M58.87M75.11M
Common Stock15K19K24K39K44K
Retained Earnings(229.93M)(274.23M)(320.89M)(358.73M)(397.56M)
Accumulated OCI(52K)150K91K90K91K
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.1M14.31M18.88M28.46M6.31M
Total Debt31.49M41.46M42.77M43.06M55.65M
Net Debt(12.44M)(563K)(3.96M)(9.61M)4.81M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.